To perform a comprehensive population genetic study of PARK2. PARK2 mutations are associated with juvenile parkinsonism, Alzheimer disease, cancer, leprosy, and diabetes mellitus, yet ironically, there has been no comprehensive study of PARK2 in control subjects; and to resolve controversial association of PARK2 heterozygous mutations with Parkinson disease (PD) in a well-powered study.
aim was to conduct a population genetic study of PARK2 and establish a reference dataset for the increasing number of PARK2disease associations that are emerging from genome-wide association studies.
PARK2 is a molecular diagnostic test for parkinsonism. The majority of positive results are heterozygous and difficult for clinicians to interpret because whether having one mutation can cause, increase risk, or accelerate onset of Parkinson disease (PD) is unknown. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] The second aim of our study was to determine, conclusively, if heterozygous mutations are associated with PD. We designed this study specifically to address this question, and to that end, amassed a large sample size to ensure analytic power, analyzed the coding regions for all types of variations, and importantly, used the same rigorous mutation analysis and validation methods in control subjects as in patients. In the first phase, we established that heterozygous point mutations are as frequent in control subjects as in patients with PD. 22 In this final phase, we present a comprehensive analysis of deletions/multiplications/copy number variations (CNV).
METHODS Subjects included 3,777 genetically unrelated individuals (1,686 control subjects and 2,091 patients with PD) from the NeuroGenetics Research Consortium (NGRC). Control subjects consisted of 1,644 white, 13 black, 11 Hispanic, 5 Asian, 4 Native American, and 9 other race/ethnicity, ages 25-99 years at blood draw (mean 66.1 Ϯ 13.1 years), and 43.8% were men. Patients with PD consisted of 1,968 white, 18 black, 31 Hispanic, 29 Asian, 9 Native American, 2 Pacific Islander, and 34 other/unknown. They were diagnosed by a movement disorder neurologist according to the modified UK PD Brain Bank criteria 23 at one of 8 NGRC clinics in Oregon, Washington, New York, and Georgia. Patients were 8 -93 years old at disease onset (58.3 Ϯ 12.1) and 21-96 years old at blood draw (mean 67.3 Ϯ 10.7 years), 67.8% were men, and 22.7% had a positive family history (first-degree or second-degree relative with PD).
Standard protocol approvals, registrations, and patient consents. The study was approved by the Institutional Review Boards of participating institutions. Informed consent was obtained from all subjects. Molecular analysis. CNV genotyping was completed for 2,091 patients and 1,686 controls using high-molecular-weight genomic DNA from blood. Genotyping was performed in phases over 7 years (details in appendix e-1 on the Neurology ® Web site at www. neurology.org). In 2004, we published on 39 patients with youngonset PD. 24 While performing the large-scale sequencing (2004 -2007) , we identified 40 subjects with rare sequence variants and genotyped them for CNVs. 22 The large-scale CNV analysis started with a modified semiquantitative PCR protocol 25 that was used for 252 patients and 299 control subjects. With the advent of PDspecific multiplex ligation-dependent probe amplification (MLPA), 26, 27 we switched to the SALSA MLPA kit P052B from MRC-Holland (Amsterdam, the Netherlands) for 1,956 patients and 1,477 control subjects. We used more conservative measures than recommended by the MLPA manufacturer and were able to establish false-positive and false-negative rates (appendix e-1). We used real-time qPCR to verify all abnormal and equivocal findings from MLPA and semiquantitative PCR. CNV carriers were sequenced for all exons to detect point mutations. Finally, using DNA from relatives, we established phase unequivocally for 39 of 52 CNV carriers.
Data analysis. Logistic regression, 2 tests, and Fisher exact tests
were used to test frequencies and estimate odds ratios (ORs) and corresponding 95% confidence intervals (95% CI). Age at onset was tested using Kaplan-Meier survival analysis, log-rank statistics, and analysis of variance. Data were adjusted for recruitment site, gender, age at blood draw, cigarette smoking, 28 caffeinated coffee consumption, 28 and PD susceptibility genotypes at SNCA REP1, 29 SNCA 5Ј promoter polymorphism rs2619364, 30 MAPT H1/H2 haplotypes, 31 and the APOE polymorphism. 32 We tested for PARK2 ϫ environment (smoking and coffee) and PARK2 ϫ genotype (SNCA, MAPT, APOE) interaction using likelihood ratio test statistics. We selected the most significant factors using backward variable selection criteria. The model goodness-of-fit was tested using Hosmer and Lemeshow test statistics. Frequencies of CNVs in patients and control subjects were visualized as a function of age using moving average plots (MAP). 33
Figure 1
Location of PARK2 copy number variations Parkinson study. The Parkinson study is described in table e-2 and figure 1. Among the 2,091 patients with PD, 13 had 2 CNVs, 5 had 1 CNV and 1 point mutation, and 18 had only 1 CNV. The mutations included deletions and multiplications in exons 2-9.
No mutations were found in exons 1 or 10 -12. All subjects with 2 PARK2 mutations had developed PD prior to age 55, which is consistent with autosomal recessive mutations causing young-onset PD. Among 171 patients with onset Յ40 years, 14 had 2 PARK2 mutations (Parkin disease) and none of the other 296 was heterozygous.
The question that we aimed to resolve was whether heterozygous mutations increase the risk or accelerate onset age of PD. Heterozygous CNV carrier frequency in patients was 0.86% (95% CI 0.46 -1.26) as compared to 0.95% (95% CI 0.48 -1.42) in control subjects. For the following analyses, we excluded subjects with mutations in LRRK2, SNCA, or SCA2 and nonwhites; the sample included 1,937 patients and 1,642 control subjects.
A striking feature of recessive PARK2 disease is the very early onset. We therefore questioned if having one mutation might accelerate onset age in common forms of PD. Mean age at onset was not earlier in PARK2 heterozygotes (64.7 Ϯ 8.6 years) than in patients lacking a PARK2 CNV mutation (58.5 Ϯ 11.8; table 1). Kaplan-Meier-generated age at onset distributions revealed a highly significant age at onset effect ( p ϭ 1 ϫ 10 Ϫ40 ), which stemmed from ϳ30 years earlier onset for patients with 2 mutations (figure 2). The Kaplan-Meier age at onset distribution for heterozygotes was not significantly different from Patients with 2 (long dashed line), 1 (short dashed line), and 0 (solid line) PARK2 mutations. Rare nonsynonymous sequence variants were considered to be a mutation only when found in an individual carrying a copy number variation (CNV). Age at onset in heterozygous PARK2 patients is not earlier than in patients lacking a PARK2 CNV mutation, as opposed to patients with compound mutations who have substantially earlier onset. The graph was generated using Kaplan-Meier survival analysis and the differences were tested using logrank statistics. Overall, p ϭ 1 ϫ 10 Ϫ40 , which is driven by compound mutation carriers in recessive young-onset disease. nonmutation carriers; in fact, heterozygotes appeared to have slightly delayed onset age (also reflected in mean onset ages), which is contrary to the hypothesis that PARK2 accelerates PD onset.
To assess PARK2 heterozygosity in relation to risk of PD, we included all patients and control subjects, regardless of age at onset or family history, and compared those with one mutation to those without. Fourteen subjects with compound PARK2 mutations were excluded. The sample included 1,923 unrelated white patients and 1,642 unrelated white control subjects. We found no evidence ( p ϭ 0.89) for association of PARK2 heterozygosity with PD risk in the overall sample (OR 1.05, 95% CI 0.50 -2.19; table 1) or in patients with positive family history (n ϭ 423, OR 0.99, 95% CI 0.28 -3.56; table 1).
We hypothesized that PARK2 heterozygosity might increase PD risk if patients also had a high-risk genotype at MAPT, SNCA, or APOE, did not smoke, did not consume large amounts of caffeinated beverages, were male, or were at advanced age. Adjusting for these factors in the model did not change the outcome (OR 1.14, p ϭ 0.82; table 1). We tested for interaction between PARK2 and the aforementioned genes and exposures, and found none ( p ϭ 0.53-0.76). We performed stepwise and backward regression, which yielded similar results. We detected significant effects on PD risk for every factor known to be associated with PD, but not for PARK2 heterozygosity. We performed numerous iterative subanalyses to search for evidence that might be hidden in the type of mutation (deletion vs multiplication), exon location (exon 2 vs 3 vs 4, for example), and mutation phase, where we assigned and analyzed seemingly contiguous deletions/multiplications once as heterozygous and once as compound (data not shown). We did not find any compelling evidence for association with PD.
The MAP ( figure 3) captures the results at a glance: mutation frequency starts very high in youngonset PD, declines sharply with increasing age at onset until it meets the control frequency at around age 45, and from age 45 until 90, stays completely superimposed on control subjects. DISCUSSION Currently, there exists no population genetic study of PARK2 in the literature. The present study fills this void. We demonstrated that PARK2 deletions, multiplications, and CNVs (this report), and rare sequence variants including point mutations (reported previously), 22 are not exclusive to disease populations. We found CNVs in ϳ1% and point mutations in ϳ3% of control subjects. Heterozygous CNV mutations in exons 2-4 are common and well-tolerated. However, we did not find any CNVs in exons 5-12 in control subjects, which include the coding region for the highly conserved functional domains of Parkin. Mutations that affect these regions may be deleterious and hence rare or absent in healthy individuals. Alterations in these exons have been observed in ARJP as recessive germline mutations, and in malignancies as heterozygous somatic mutations. None of the 1,686 control subjects was homozygous or compound heterozygous, which implies biallelic mutations are pathogenic. This is certainly the case for ARJP. We do not know, however, if recessive genotypes can cause disorders other than ARJP.
The second component of the study, the role of PARK2 in common PD, addressed a much-debated and extensively published controversy. 9-21 Studies Moving average plots of PARK2 mutation frequency as a function of age
Moving average frequency of PARK2 mutations was estimated as a function of age at onset in patients (red triangles) vs age at blood draw in controls (blue circles) with 95% central posterior probabilities (red and blue lines). Plots show that PARK2 mutation frequency is very high in young-onset Parkinson disease (PD), declines with increasing age at onset, and by age 45 and thereafter, the mutation frequency in PD and control subjects are completely superimposed. Gray bars at the bottom of the graph show the statistical significance of the difference between patients and control subjects, calculated in the moving window (light gray Ն95% probability, dark gray Ն99% probability). Due to few numbers at the extremes, subjects with ages Յ20 or Ն90 years were merged.
have reported heterozygous mutations in patients that were absent in controls, suggesting PARK2 heterozygosity is a risk factor for PD. [10] [11] [12] [13] [14] 16, 17 However, not all studies found a higher frequency in patients than in controls. 20 Although the sampling of patients varied across studies (early-onset, late-onset, familial PD), the frequency of PARK2 mutations in our patients with PD, when subgrouped to match each study, are generally in line with most prior studies. The main difference between our data and most other published datasets is in the controls. The frequency of PARK2 mutation in our controls is higher than most, but is in line with Lincoln et al. 20 and Bruggemann et al., 21 who, like us, genotyped controls comprehensively. Most other studies performed detailed genotyping in patients and screened control subjects only for the mutations found in patients; thus, we suspect, missed the mutations that might have been present in controls but not in patients. The 3 studies that genotyped controls comprehensively had sample sizes of 192, 20 356, 21 and 1,686 (this study), and all 3 report 3%-4% of controls carrying heterozygous PARK2 mutations. A study of familial PD, however, found no CNV mutations in 263 control subjects, which was significant compared to their patient population. 14 Our study had 99% power to detect the effect size reported for familial PD, 14 and ϳ90% power to detect a minimum OR of 1.5 overall; yet our OR and p values were ϳ1.
The varied results of published data may be consolidated as follows when 2 key variables are considered: age and genotyping method. 1) PARK2 mutation frequency is high in young-onset PD and drops sharply with increasing onset age, as clearly shown in figure  3 . 2) Having PARK2 mutations on both chromosomes causes disease, which is well-established. 3) Having one mutation occurs at a low frequency (Ͻ5%) in both patients and control subjects, and is detectable only when the sample size is large and rigorous genotyping methods are used.
There are caveats to our study. Results cannot be generalized to nonwhite populations, nor do they speak to subclinical disease that may be present in heterozygotes. 18 Interaction tests had low power. It is possible that a single PARK2 mutation is a "silent" etiologic factor that manifests clinically in combination with as yet unknown PD triggers. 
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